Mackenroth J, Hölig K, Kuhlisch E, Siegert G, Suttorp M
Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden.
Klin Padiatr. 2008 May-Jun;220(3):153-8. doi: 10.1055/s-2008-1065344.
In humans approx. 10% of the total body selenium (Se) content is present in the blood being evenly distributed among plasma and red cells. The important role of Se in antioxidative biological pathways is proven. Many parents of children with malignancies ask for supplementation with Se as part of complementary therapy during or after the oncological treatment. However, toxic Se concentrations may easily be reached in children. In order to analyse whether Se is also supplied by red cell transfusions (RCT), we determined Se concentration in whole blood prior and after packed RCT in pediatric patients with hemato-oncological diseases.
EDTA-blood was collected from 17 patients (median age: 4 years, range: 1 month - 17 years) with aplastic anemia, acute leukemia and solid tumours prior and after RCT (n=60). Patients received a median of 2 transfusions (range: 1-14). Samples were also collected from the transfusion blood bags and Se concentration was determined quantitatively by atomic absorption spectrometry.
95% of the specimen collected from the transfusion bags exhibited selenium concentrations within the normal adult range. Mean Se concentration in the patients' blood prior to RCT was 66.2 microg/l (range: 38.0-166.4 microg/l) and increased to 70.7 microg/l (range: 14.1-105.1 microg/l) thereafter (statistically not significant). Applying age dependant reference values Se concentrations were below the lower limit in 45% of the samples prior to RCT and only in 26% after RCT. The reason for this increase was the fact that Se concentrations were often just marginally below the age-dependant lower limit prior to RCT and in the lower normal range thereafter.
43% of the patients with hemato-oncological diseases in this study exhibited no Se deficiency at any time point. In the remaining 57% of the patients a transient or persistent Se deficiency was detected with blood levels partially far below the lower threshold of the age adjusted normal range. The Se deficiency was corrected in four out of eight patients by RCT. As Se levels may fluctuate in individual pts a supplementation should only be initiated if based on regular monitoring of the Se concentration.
在人类中,全身硒(Se)含量的约10%存在于血液中,在血浆和红细胞中均匀分布。硒在抗氧化生物途径中的重要作用已得到证实。许多患有恶性肿瘤儿童的家长要求在肿瘤治疗期间或之后补充硒作为辅助治疗的一部分。然而,儿童很容易达到硒的中毒浓度。为了分析红细胞输血(RCT)是否也能提供硒,我们测定了血液肿瘤疾病儿科患者进行浓缩红细胞输血前后全血中的硒浓度。
收集了17例再生障碍性贫血、急性白血病和实体瘤患者(中位年龄:4岁,范围:1个月至17岁)在红细胞输血前后(n = 60)的乙二胺四乙酸(EDTA)抗凝血。患者接受的输血中位数为2次(范围:1 - 14次)。还从输血血袋中采集样本,并通过原子吸收光谱法定量测定硒浓度。
从输血袋中采集的95%的样本中硒浓度在正常成人范围内。患者输血前血液中的平均硒浓度为66.2微克/升(范围:38.0 - 166.4微克/升),之后升至70.7微克/升(范围:14.1 - 105.1微克/升)(无统计学意义)。应用年龄相关参考值时,输血前45%的样本中硒浓度低于下限,输血后仅26%低于下限。这种升高的原因是,输血前硒浓度通常仅略低于年龄相关下限,之后处于较低的正常范围内。
本研究中43%的血液肿瘤疾病患者在任何时间点均无硒缺乏。在其余57%的患者中,检测到短暂或持续的硒缺乏,其血硒水平部分远低于年龄调整正常范围的下限。8名患者中有4名通过红细胞输血纠正了硒缺乏。由于个体患者的硒水平可能波动,只有在定期监测硒浓度的基础上才应开始补充硒。